ITL BioMedical, a division of ITL Health Group (ASX:ITD), that sets industry standards for the innovative design and production of biological sampling systems, is pleased to announce a contract extension of 12 months with a large US community blood bank for its SampLok® Sampling Kit (“SSK”). ITL BioMedical has been a supplier to this blood center for over four years.
Read More “ITL Wins SSK Contract Extension with US Blood Bank”
ITL Health Group (ASX:ITD) is pleased to provide the opportunity to listen to an audio interview with Mr. Bill Mobbs, Executive Chairman, following the release of the Company’s Full Year Results today.
Read More “Interview with Bill Mobbs discussing Full Year Results”
ITL Health Group (ASX:ITD) is pleased to announce financial results for the year ending 30 June 2017 that show considerable year on year profit growth.
ITL Health Group (ASX:ITD), is pleased to announce that its wholly owned subsidiary MyHealthTest Pty Ltd (MHT), the direct to consumer pathology test provider, achieved considerable public interest during National Diabetes Week.
Read More “National Diabetes Week Drives Demand for MyHealthTest”
ITL BioMedical, a division of ITL Health Group (ASX:ITD), that sets industry standards for the innovative design and production of biological sampling systems, is pleased to announce that the Pró-Sangue blood center in Brazil has begun using ITL’s SampLok® Sampling Kit (SSK).
Read More “Largest South American Blood Center Initiates Use of ITL’s SSK”
ITL Health Group (ASX:ITD), is pleased to announce that its wholly owned subsidiary MyHealthTest Pty Ltd (MHT), the direct to consumer pathology test provider, has been awarded a $2.6m CRC-Project grant for the development of new health testing methods using dried blood spot samples. Read More “MyHealthTest awarded $2.6m CRC Project Grant”
ITL Health Group is pleased to provide the opportunity to listen to an audio interview with Mr. Bill Mobbs, Executive Chairman.
Read More “Boardroom Media Interview: Positive Full Year Results Expected”
ITL Health Group (“ITL”), an innovative global medical technology company, expects to announce very positive results for the financial year to 30 June 2017. Read More “ITL Announces Positive Full Year Trading Update”
MyHealthTest (MHT), a division of ITL Health Group (ASX:ITD) that creates and markets highly innovative direct to consumer pathology testing for major chronic diseases, is very pleased to announce it has been granted accreditation for its testing laboratory to the ISO15189 and NPAAC (National Pathology Accreditation Advisory Council) standards by the National Association of Testing Authorities (NATA) and the Royal College of Pathologists of Australasia (RCPA).
Read More “MyHealthTest Achieves Major Milestone of Laboratory Accreditation”
ITL Health Group (ASX:ITD), an innovative global medical technology company, is pleased to announce that in February the Company recorded its highest monthly revenue and profit in its 23-year history. ITL BioMedical and ITL Healthcare both achieved record months. Read More “ITL Achieves Record Month”
